

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **RSC Advances**

2 **Full Length Article**

3 **Urinary metabolomics study on an induced-stress rat model using UPLC-QTOF/MS**

4 Yuan-yuan Xie †^a, Li Li †^{a,b}, Qun Shao^{c,*}, Yi-ming Wang^a, Qiong-Lin Liang^a, Hui-Yun Zhang^e, Peng
5 Sun^e, Ming-qi Qiao^e, Guo-An Luo^{a,d*}

6 *^aDepartment of Chemistry, Tsinghua University, Beijing, PR China, 100084.*

7 *^bThe Second College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, PR
8 China, 510120.*

9 *^cSchool of Life Science, University of Bradford, Bradford, West Yorkshire, UK, BD71DP.*

10 *^dState Key Laboratory for Quality Research in Chinese Medicine, Macau University of Science and
11 Technology, Avenida Wai Long, Taipa, Macau, PR China*

12 *^eShandong University of Traditional Chinese Medicine, Jinan, PR China*

13

14

15

16 †These authors contributed equally to work.

17 Address correspondence to:

18 * Prof. Guo-an Luo

19 Department of Chemistry, Tsinghua University, Beijing 100084, P.R. China

20 Tel/Fax: +86-10-62781688, E-mail: luoga@mail.tsinghua.edu.cn.

21 * Doctor Qun Shao

22 School of Life Science, University of Bradford, Bradford, West Yorkshire, BD71DP, UK.

23 Tel: +86-44-(0)1274 236041, Fax: +86-44-(0)1274 236155 E-mail: q.shao@bradford.ac.uk

24 Abstract

25 A urinary metabolomics method based on ultra-performance liquid chromatography coupled with
26 quadrupole/time-of-flight mass spectrometry (UPLC-QTOF/MS) was employed to investigate the
27 pathogenesis and therapeutic effects of a *Baixiangdan* capsule on rats undergoing electric-induced stress
28 for five days. Multivariate analysis techniques, such as principal component analysis (PCA) and partial least
29 squares-discriminant analysis (PLS-DA), were applied to observe the temporal changes in the metabolic
30 states of the electric-stressed rats visually, as well as the recovering tendency of the rats treated with the
31 *Baixiangdan* capsule. Artificial intelligence technology (artificial neural networks and neurofuzzy logic)
32 was used to identify the potential biomarkers, and the results showed a high overlap with the PLS-DA
33 model. A total of 14 potential biomarkers representing major cause-effect relationships between the
34 variations in the endogenous metabolites and the dynamic pathological processes associated with the
35 stress induced by the electric stimulation were identified, including amino acid metabolites, such as
36 2-aminoadipic acid, hippuric acid, spermine, 4-hydroxyglutamate and L-phenylalanine, in addition to
37 prostaglandin F3a and melatonin. The results indicated that the pathways corresponding to
38 L-phenylalanine, tyrosine, tryptophan, arginine, proline metabolism, pantothenic acid, and coenzyme A
39 synthesis were disturbed in the electric-stressed rats, and the application of the *Baixiangdan* capsule may
40 regulate the aforementioned metabolic pathways back to their initial states. The application of artificial
41 intelligence technologies provided powerful and promising tools to model the complex metabolomic
42 data and to discover hidden knowledge regarding the potential biomarkers associated with the
43 development of disease, which is also suitable for other complex biological data sets.

44 **Keywords:** metabolomics, urine, premenstrual syndrome, UPLC-QTOF/MS, artificial intelligence,
45 biomarkers

46 1. Introduction

47 Metabolomics, one of the major platforms in systems biology, is used to study perturbations in response
48 to physiological challenges, toxic insults or disease processes by measuring low-molecular-weight
49 metabolites (<1 kDa) and their dynamic changes in complex biological samples ¹⁻³. Recently, an
50 increasing number of publications described the application of metabolomics approaches in traditional
51 Chinese medicine (TCM) research, which demonstrates that metabolomics is a powerful tool for
52 assessing the holistic efficacy of TCM formulae because the global metabolic state of an entire organism
53 can be represented *via* a single metabolic profile analysis ⁴⁻⁶. Normally, information-rich metabolomics
54 data are acquired from high-field nuclear magnetic resonance (NMR) ⁷, gas chromatography mass
55 spectrometry (GC-MS) ⁸, or/and UPLC-QTOF/MS ⁹. Furthermore, many multivariate analysis
56 techniques, such as principal component analysis (PCA), partial least squares discriminant analysis
57 (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA) and support vector
58 machine recursive feature elimination (SVM-RFE), are commonly used to find informative biomarkers
59 for subsequent studies ¹⁰⁻¹¹.

60 Neurofuzzy logic, which combines the adaptive learning capabilities of artificial neural networks (ANNs)
61 with the generality of representation from fuzzy logic, is one of the artificial intelligence (AI)
62 technologies that had proven to be an effective tool for analysing complex biological data sets ¹². Fuzzy
63 logic modelling implementing the adaptive B-spline modelling of observation data (ASMOD) algorithm
64 can be applied to generate a number of training models and perform training tests to determine which
65 one best fits the data. The quality of the models is assessed using various statistical fitness criteria, e.g.,
66 Akaike's Information Theoretic Criterion (AIC), final prediction error (FPE), cross validation (CV),
67 generalised cross validation (GCV), minimum descriptor length (MDL) and structure risk minimization
68 (SRM). These aim at minimizing a criterion containing two terms—one involving the prediction errors

69 computed in the data set and the other involving the complexity of the structure of the trained models.
70 These training parameters are then investigated to obtain the ideal model with best predictions of the
71 validation data, as well as generating intelligible rules in an “if then” format that explicitly represents the
72 cause-effect relationships contained in the experimental data. During the training process, the
73 improvement of the model training is assessed via these fitness criteria, which is different from the cross
74 validation approach commonly applied in neural networks, where the test data are used. In this method,
75 neural networks are used to optimise certain parameters of the fuzzy systems and automatically extract
76 fuzzy rules from the numerical data. Five back propagation learning algorithms, including Standard
77 Incremental, Standard Batch, RPROP, Quickprop, and Angle Driven Learning, are used to adjust the
78 weights of the network connections during the training. A change in the weights will affect the
79 contribution of each input variable and therefore largely influence the way that a trained network gives
80 predictions ¹³. Neurofuzzy logic had been successfully applied in tablet film coatings, pharmaceutical
81 formulations and processing ¹⁴. However, the application of neurofuzzy logic in metabolomics data
82 analysis to discover hidden knowledge regarding potential biomarkers associated with the development
83 of disease remains relatively new.

84 Premenstrual syndrome (PMS), a typical stress-related emotional disease affecting 8 % of women of
85 child bearing age, is a collection of emotional symptoms, with or without physical symptoms, related to
86 a woman’s menstrual cycle. Emotional symptoms, referred to as premenstrual dysphoric disorder
87 (PMDD), such as depression and anxiety, must be consistently present to diagnose PMS ¹⁵. Although
88 the duration of PMS symptoms are shorter than depression due to other etiologies, such as severe
89 depression, post-traumatic stress disorder and anxiety disorders, their influences on the quality of life of
90 a patient in the luteal phase can be as great as or worse than other disorders. PMS has attracted much
91 attention in the international medical community, though the exact etiology remains unclear even after

92 more than 40 years of systematic research¹⁶. The theory of TCM believes that the pathogenesis of PMS
93 is closely related to liver dysfunction, in which liver-Qi invasion syndrome and liver-Qi depression
94 syndrome are the two principal subtypes¹⁷. Therefore, TCM formulae that function to smooth the liver
95 and regulate vital energy are normally used to relieve the symptoms of PMS¹⁸. The *Baixiangdan*
96 capsule is a novel modernised composite medicine prepared using Radix Paeoniae alba and Cortex
97 moutan radiceis extracts, together with Rhizoma Cyperi volatile oil, which exhibits a favourable efficacy
98 for the treatment of PMS due to liver-Qi invasion syndrome¹⁹.

99 The electrical stimulation of female Sprague-Dawley (SD) rats produces a series of abnormal
100 behavioural and physiological responses similar to the symptoms of liver-Qi invasion syndrome PMS
101 in humans, and it is often used as an animal model to study the pathogenesis of PMS²⁰. The feasibility
102 of establishing a model of liver-Qi invasion syndrome PMS in SD rats using electrical stimulation has
103 been proven²¹. Previously, a serum metabolomics approach based on UPLC/QTOF-MS was developed
104 to evaluate the therapeutic effects of the *Baixiangdan* capsule on liver-Qi invasion syndrome PMS in
105 rats. The therapeutic mechanism of the *Baixiangdan* capsule is related to the regulation of metabolism
106 by corticosteroids (e.g., tetrahydrodeoxycorticosterone, 5 α -tetrahydrocortisol, epinephrine), oestrogen
107 (e.g., pregnanediol, estrone) and excitatory/ inhibitory amino acid neurotransmitters (e.g., lysine,
108 5-hydroxylysine, acetylcysteine)²². In the present study, we applied a urinary metabolomics method to
109 investigate the time-related biochemical abnormalities in liver-Qi invasion syndrome PMS due to
110 electrical stimulation for 5 days and assessed the therapeutic effects of the *Baixiangdan* capsule.
111 Artificial intelligence technology (artificial neural networks and neurofuzzy logic) was used to identify
112 the metabolic pathways and the potential biomarkers related to PMS to achieve the most comprehensive
113 metabolome coverage and provide a more in-depth understanding of the pathophysiological processes of
114 PMS.

115

116 **2. Material and methods**

117 **Chemicals and reagents**

118 HPLC-grade acetonitrile was purchased from J. T. Baker (Phillipsburg, NJ, USA). The following
119 compounds were obtained from Sigma-Aldrich (Louis, Mo, USA): 2-aminoadipic acid, hippuric acid,
120 spermine, 4-hydroxyglutamate, L-phenylalanine, melatonin, L-methionine, proline, genistein and
121 leucine-enkephalin. Ultrapure water (18.2 M Ω) was prepared using a Milli-Q water purification system
122 (Millipore, France). All of the other chemicals that were used were analytical grade.

123 The *Baixiangdan* capsule was a TCM prescription prepared using Radix Paeoniae alba extract, Cortex
124 moutan radices extract and Rhizoma Cyperi volatile oil, which was provided by Shandong Traditional
125 Chinese Medicine University. The preparation process was strictly carried out according to the fixed
126 processing parameters. The *Baixiangdan* capsules used in this study were placed under a careful quality
127 control to ensure their identity throughout all of the experiments. Three representative components
128 (paeoniflorin, paeonol and α -cyperone) were used as quality indicators during the HPLC evaluation²³.

129

130 **Animal handling and sample collection**

131 Healthy and non-pregnant female Sprague-Dawley rats (190-200 g in weight) were supplied by the
132 Experimental Animal Center of Shandong Traditional Chinese Medicine University (serial number
133 SCXK (Lu) 20050015 on the certificate of conformity, Jinan, China). All of the animals were
134 maintained in an environmentally controlled room under a controlled temperature (22–25°C) and
135 relative humidity (50 \pm 5 %) on a 12 h light/dark cycle (lights on from 08:00 to 20:00). The experiments
136 were conducted in a specific pathogen free (SPF) grade laboratory according to the guidelines provided
137 in the Guiding Principles for the Care and Use of Laboratory Animals approved by the Committee for

138 Animal Experiments at Shandong Traditional Chinese Medicine University (Jinan, China). The animals
139 were acclimated for 1 week before use. A standard diet and water were provided to the rats *ad libitum*.
140 A total of 30 animals in diestrus and metestrus were selected using vaginal smears together with the
141 behavioural assessment described previously²⁰. The animals were randomly divided into the following
142 3 groups with 10 rats in each group: (1) control group (CG), (2) stress group (SG), (3) *Baixiangdan*
143 capsule-dosed group (BCDG). Each rat was maintained in an individual tailor-made cage. The PMS rat
144 model was produced using electrically induced stimuli with a digital pulse stimulator²¹. The SG and
145 BCDG rats were treated with the electrically induced stimuli (0.5 mA pulses at a voltage of 2700~3300
146 V and a pulse width of 0.3 s) continuously for 5 days. Each application of the electric stimuli lasted for
147 5 minutes twice during the day and for 10 minutes three times in the evening. The BCDG rats were
148 administered a water solution of the *Baixiangdan* capsule at a dose of 10 mL/ kg·w·d (1 mL of the
149 solution is equivalent to 1 g of the crude herbs) via an intra-gastric gavage once a day, amounting to
150 eight times the clinical dosage. Meanwhile, the CG and SG rats were administered the same volume of
151 water via oral gavage. The 24-h urine samples were collected over the 5-day electric-stimuli period.
152 The urine samples at the starting point (without electric stimuli, day 0) were collected 24-h prior to the
153 start of the experiment. The collected urine samples were stored at -80°C until the sample preparation.
154 Because of the individual differences between the rats, not all of the rats urinated regularly every 24 h.
155 At the end of the experiment, only 140 urine samples were collected for the UPLC-QTOF/MS analysis.

156

157 **Sample preparation**

158 Prior to the analyses, the samples were thawed at room temperature. The urine samples were
159 centrifuged at 13000 rpm for 20 min at 4°C, then the supernatant was analysed via UPLC-QTOF/MS.
160 Three parallel sample solutions were prepared and analysed for accuracy.

161

162 UPLC-QTOF/MS Analysis

163 The chromatographic separation was performed on an ACQUITY UPLC BEH C₁₈ column (2.1×100
164 mm, 1.7 μm, Waters Corp, Milford, MA, USA) using a Waters ACQUITY UPLC™ system equipped
165 with a binary solvent delivery system, an auto-sampler, and a PDA detector. The column was
166 maintained at 30°C and eluted at a flow rate of 0.4 mL/min, using a mobile phase of water with 0.2 %
167 (by volume) formic acid (A) and acetonitrile (B). The gradient program was optimised as follows: 0-18
168 min, 0 % B to 35 % B; 18-20 min, 35 % B to 95 % B; 20-22 min, 95 % B; 22-25 min, 95 % B to 0 % B;
169 25-28 min, equilibration with 0 % B. The column eluent was directed to the mass spectrometer without
170 a split.

171 The mass spectrometry was performed on a Waters Q-TOF Premier mass spectrometer (Waters Corp.,
172 Manchester, UK) with the electrospray ionization source (ESI) operation in the positive ion mode (“V”
173 mode of operation). The ESI-MS parameters for LC/TOF-MS were: capillary voltage 3200 V; cone
174 voltage 35 V; nitrogen was used as the drying gas, and the desolvation gas flow rate was set as 700 L/h
175 at a temperature of 350°C; cone gas rate was 50 L/h; source temperature 110°C; The scan time was 0.1s;
176 inter-scan delay was 0.02 s. All of the analyses were acquired using an independent reference
177 lock-mass ion via the LockSpray™ interface to ensure accuracy and reproducibility.
178 Leucine-enkephalin was used as the reference compound (*m/z* 556.2771 for the negative-ion mode) at a
179 concentration of 50 pg/μL and flow rate of 10 μL/min. The data were collected in the centroid mode
180 from *m/z* 50 to *m/z* 1000 using a LockSpray frequency of 10 s, and the data were averaged over 10
181 scans for the correction.

182

183 Data Processing

184 The data were combined into a single matrix by aligning the peaks with the exact mass / retention time
185 pair (EMRT) from each data file along with their associated intensities using MarkerLynx Applications
186 Manager version 4.1 (Waters Corp., Manchester, UK). The parameters included a retention time (t_R)
187 range from 0 to 28 min, a mass range from 50 to 1000 Da, and the mass tolerance was 0.02 Da. The
188 minimum intensity was set at 15 % of the base peak intensity, the maximum mass per t_R was set at 6,
189 and the t_R tolerance was set at 0.02 min. An original data list was obtained using a database (peak
190 matrix) containing 421 data records (144 data records were obtained from the stress group, 127 data
191 records were obtained from the *Baixiangdan* capsule-dosed group and 150 data records were obtained
192 from the control group) and 4000 independent variables (biochemical substances). Prior to the
193 multivariate statistical analyses, the data from each chromatogram were normalised to a constant
194 integrated intensity relative to the number of peaks to partially compensate for the concentration bias of
195 each sample. The processing of the data normalization had little effect on the conclusion of the
196 trajectory analysis, which aimed to improve the clustering tightness in the PLS-DA model by
197 comparing the results of the area-normalised data model with that of the non-normalised data model
198 (data were not shown). The between-subject data X was then Pareto-scaled to facilitate the analyses of
199 the major effects in the data. Upon grouping the information, the processed original data list was then
200 divided into three datasets and exported and processed via PCA and PLS-DA analyses using the
201 software package SIMCA-P version 11.5 (Umetrics AB, Umeå, Sweden).

202 Two commercial AI software tools representing the two technologies were used in this study:
203 INForm4.3 for the neural networks and FormRules 3.0 for the neurofuzzy logic. Both software
204 packages were provided by Intelligensys Ltd., UK. The algorithm and data processing methods of these
205 two software programs are as follows, and have also been described previously^{13-14, 23}. For the data
206 preprocessing of the AI analysis, PCA was initially applied to reduce the dimensions of the SG dataset

207 containing the 144 data records, from 4000 independent variables to 140, according to the significance
208 of the contribution to the PCA model. FormRules 3.0 implements the ASMOD algorithm to generate
209 the neurofuzzy logic model, which enables the discovery of differential features (potential biomarkers).
210 The reduced variable dataset containing only the discovered differential features as independent
211 variables was established during the neurofuzzy logic modelling, and the hidden relationships among
212 the these differential features were also discovered. Structure Risk Minimization (SRM) was used to
213 assess the quality of the models in this study. INForm 4.3, which is embedded with a multi-layer
214 perceptron neural network, was applied to validate the robustness of the discovered differential features
215 by comparing the quality of the models based upon the original dataset and the reduced variable dataset.
216 One of the back-propagation learning algorithms, such as Standard Incremental, Standard Batch,
217 RPROP, Quickprop and Angle Driven Learning, was selected to obtain the optimal prediction accuracy.
218 The work flow of the data analyses using the AI techniques is shown in Figure 1.

219 **Figure 1 The work flow of the data analyses using AI techniques, including reducing the**
220 **variables using a neurofuzzy logic model and the predictive ability assessment using**
221 **a neural network model.**

223 3. Results

224 Establishment of the metabolic fingerprints

225 To optimize the experimental conditions, a pre-investigation had been conducted before the full study.
226 The fingerprints of a small batch of test urinary samples were acquired in both the positive and negative
227 mode. Higher noise and matrix effect in ESI negative mode had been observed. The higher baseline in
228 ESI negative mode led to the neglect of some low abundance metabolites and the concomitance of
229 multiple adduction ions. After considering the maximization of the number of detectable metabolites and

230 the quality of the acquired data, the full-scan detection was eventually set in ESI positive mode. After a
231 careful optimisation of the flow rate and the column temperature for the chromatography and the
232 capillary voltage, flow, and the temperature of the desolvation gas for the mass spectrometry detector,
233 the optimal parameters were fixed as listed in *section 2.4*. As a result, a higher flow rate (0.4 mL/min)
234 was used to achieve higher analysis efficiency on the UPLC column and to reduce the run time.
235 Meanwhile, the tolerance in the backpressure elevation and the effect on the spray and desolvation were
236 also considered. The flow and temperature of the desolvation gas were set at 700 L/h and 350°C,
237 respectively, to remove any redundant solvent resulting from the high flow rate and to improve the
238 efficiency of the desolvation and ionization. Using the optimised conditions, the representative base
239 peak intensity chromatograms of the rat urine obtained in ESI positive mode for the different groups are
240 shown in Figure 2. After completing the processing described in Section 2.5, a list of 4000 compounds
241 was exported for each sample, and the standard quality control (QC) samples were pooled (small
242 aliquots of each biological sample to be studied were pooled and thoroughly mixed). Between each
243 analytical unit of 20 analytes, the QC sample was analysed to provide a robust quality assurance for
244 each metabolic feature that was detected. The precision and repeatability of the UPLC-MS method
245 were validated via a duplicate analysis of six injections of the same QC sample and six parallel samples
246 prepared using the same preparation protocol, respectively. The relative standard deviations of the
247 retention time and area were less than 5.0 %. The resulting data showed that the precision and
248 repeatability of the proposed method were satisfactory for metabolomics analysis.

249

250 Figure 2 Representative base peak intensity chromatogram of the rat urine obtained in ESI positive
251 mode based of UPLC-QTOF/MS. (A) control group (CG); (B) stress group; (C) *Baixiangdan* capsule
252 dosed group (BCDG).

253

254 **Urinary metabolic profiling data processing using PCA and PLS-DA**

255 The PCA and PLS-DA analyses of the dataset containing 144 data records obtained from the SG rats on
256 days 0 (prior to the electrically induced stress), 1, 2, 3, 4 and 5 were performed first. The PCA score
257 plot (Figure S1) showed clear differences between the urine samples collected on days 0, 1, 2, 3, 4, and
258 5, which visualised the general changes in the holistic metabolic profile of the endogenous metabolites
259 during the electric stimulations.

260 The supervised pattern recognition (PLS-DA) was more focused on the actual class discriminating
261 variations compared to the unsupervised approach (PCA). Figure S2 (A) shows the score plot of the
262 PLS-DA model using the dataset from the SG rat urine samples to discriminate between the different
263 days of induced stress, and it is similar to the PCA result. The parameters of this PLS-DA model were
264 $R^2X_{(cum)}=0.427$, $R^2Y_{(cum)}=0.952$, $Q^2Y_{(cum)}=0.912$, which means that 42.7 % of the independent variables
265 were applied to construct the model, 95.2 % of the samples (data records) fit the established discriminant
266 mathematic model, and the prediction accuracy of this model was 91.2 %. After being processed via
267 PLS-DA in SIMCA-P, the mean-centred PLS-DA score plots were generated to trace and compare the
268 dynamic changes in the metabolic events in the rats undergoing electric stimulation for 5 days. In the
269 PLS-DA graph, each spot represented a sample and each assembly of samples indicated a particular
270 metabolic pattern at a different time point. The loci marked by arrows represent the trend of the mean
271 metabolite pattern changes. As shown in Figure S2 (A), the metabolic state of each group on day 1 had
272 deviated from the initial position (day 0, prior to the electrically induced stress), and the greatest
273 difference was observed on day 2, which indicates that in response to the electric stimulation, the
274 metabolism of the endogenous substances and the metabolic profiles of the urine compared to the initial
275 state (day 0) were significantly altered. From day 3 to day 5, the trajectory direction gradually returned

276 to that observed on day 1, indicating the recovery of the disturbed metabolic state. The VIP (variable
277 importance in the projection) value of each variable in the model was ranked according to its
278 contribution to the classification. The VIP list of the retention time-exact mass pairs was obtained from
279 the PLS-DA using SIMCA-P. To select the potential biomarkers worthy of preferential study in the next
280 step, these differential metabolites were validated using Student's *t* test. The critical *p*-value was set to
281 0.05 for the significantly different variables in this study. Following the criteria listed above, 14
282 significantly different endogenous metabolites present in the urine of on the 5th day were selected for
283 further study. The identification of the potential biomarkers was then carried out as follows, and the
284 results are listed in Table 1. The possible elemental compositions of the selected compounds were
285 generated using the software program Masslynx according to the following procedure: the calculated
286 mass, mass deviation (mDa and ppm), double-bond equivalent, formula, and *i*-fit value (the isotopic
287 pattern of the selected ion) were calculated using the selected *m/z* ions. A lower *i*-fit value and smaller
288 mass deviation indicate a more accurate elemental composition. The structural information was
289 obtained by searching freely accessible databases (KEGG (<http://www.genome.jp>) and HMDB
290 (<http://www.hmdb.ca>)) using the detected molecular weights and elemental compositions.

291 As a result, 14 potential biomarkers were identified based on the accurate elemental compositions and
292 the retention time and 9 were confirmed using the available reference standards by matching their
293 retention time and accurate mass measurement. Among them, 2-aminoadipic acid (**1**), 5-oxoproline (**2**),
294 shikimate-5-phosphate (**4**), 4-hydroxyglutamate (**5**), hippuric acid (**10**), 5-(2-hydroxyethyl)-4-
295 methylazole (**11**) and melatonin (**13**) were found to be increased in the urine samples from the
296 electric-stressed rats compared to their initial state. Conversely, prostaglandin F3 α (**3**), biocytin (**6**),
297 genistein (**7**), deoxyadenosine (**8**), 6-keto-prostaglandin F1 α (**9**), 2,3-diaminopropionic acid (**12**) and
298 5-amino-valerate (**14**) were decreased²³.

299 Meanwhile, the MS spectra dataset of the CG rats during the five testing days were also analysed using
300 PLS-DA. Compared to the pathological variations observed in the SG rats, the trajectory of the CG rats
301 was irregular, as shown in supporting information Figure S3, which suggests that the electric stimuli on
302 female rats may lead to systemic metabolic variation. To determine the treatment-related metabolic
303 pattern alterations, another PLS-DA model ($R^2X_{(cum)}=0.423$, $R^2Y_{(cum)}=0.973$, $Q^2Y_{(cum)}=0.877$) was
304 constructed with a dataset containing 127 data records obtained from the BCDG rats. As shown in
305 Figure S2 (B), a classification between different treatment days was clearly achieved, and the trajectory
306 of the metabolic profiles illustrated the temporal metabolic variations in the urine metabolites and
307 exhibited a recovering tendency back to the initial state (day 0) following treatment with the
308 *Baixiangdan* capsule.

309

310 **Feature selection and identification of the significant metabolites using AI technology**

311 Due to the complexity and nonlinearity of metabolomics data, AI technologies provide a meaningful
312 method for the discovery of feature information hidden in data. Neural networks are computational
313 systems capable of mimicking the mechanisms of human learning. They enable the detection of
314 complex relationships between a set of inputs and outputs and estimate the magnitude of the
315 relationships without requiring a mathematical description of how the output is functionally dependent
316 on the input. They are useful for processing unstructured and nonlinear data for the recognition of
317 patterns in high-dimensional data. Neurofuzzy logic is a hybrid AI technology that combines the
318 learning capabilities of neural networks with the generality of fuzzy logic, and it is able to generate
319 knowledge regarding the patterns hidden in data in an interpretable format¹³.

320 In this study, the top 140 independent variables were selected from the ranking order generated by the
321 PCA according to the significance of its contribution to the PCA model. A reduced variable dataset was

322 then formed, which included the 140 independent variables from the original dataset. Further data
323 mining activities were then conducted using this new dataset, and the ASMOD algorithm was applied
324 to generate the neurofuzzy logic model. A total of 14 independent variables were discovered to be
325 differential features. Therefore, two datasets that included the same data records but different
326 dimensions (number of independent variables), in which one contained the 140 variables and the other
327 contained the 14 selected differential features as independent variables, have been established. Next, a
328 further investigation using a multi-layer perceptron neural network was carried out to validate the
329 robustness of the discovered reduced variable dataset by comparing the quality of the models based on
330 the two established datasets. During the modelling process, the two datasets were both randomly
331 divided into a validation set (28 data records, 20 % of the 144 data records were selected using the
332 “Smart Selection” function in INForm4.3) and a training set (116 data records, the remaining 80 % of
333 the 144 data records). Two neural network models were generated using the two selected training set
334 datasets. Then, the predictabilities of these two neural network models were tested against the validation
335 datasets. The validation R^2 that was computed using the validation dataset was used to evaluate the
336 predictability of the neural network model. As shown in Figures 5, the validation R^2 of the validation
337 dataset containing the 140 independent variables is 0.9506 (Figures 3A), and it is 0.9539 (Figures 3 B)
338 for the 14 discovered differential features (independent variables) after reducing the dimensions using
339 neurofuzzy logic. The similarity between the validation R^2 values indicates that the predictability of the
340 neural network model did not deteriorated by reducing the dimension. The major knowledge of the
341 relationships between the independent variables and the dependent variables (Grouping Information)
342 still remains in the reduced variable dataset. The 14 discovered differential features are sufficient to
343 explain the variability associated with the relationship between the independent and dependent variables
344 (Grouping Information) and to represent the cause-effect relationships between the variations in the

345 endogenous metabolites and the dynamic pathological processes associated with the stress induced by
346 the electric stimulation. Therefore, the 14 differential feature metabolites discovered via AI analysis
347 were considered to be potential biomarkers related to the development of induced stress. They were
348 identified using the methods described in *section 3.3*. As shown in Table 1, eight of the potential
349 biomarkers, including 2-aminoadipic acid (**1**), prostaglandin F_{3α} (**3**), shikimate-5-phosphate (**4**),
350 4-hydroxyglutamate (**5**), genistein (**7**), hippuric acid (**10**), 2,3-diaminopropionic acid (**12**) and
351 melatonin (**13**), were discovered by both the PLS-DA and the AI analysis. The six remaining
352 differential metabolites were only discovered by the AI, of which, spermine (**15**), L-phenylalanine (**16**),
353 pantothenol (**18**) and xanthosine (**20**) were significantly decreased in the electric-stressed rats, whereas
354 proline (**17**) and L-methionine (**19**) were significantly increased.

355 Figure 3 The predictions given by the ANN models generated using a dataset containing various
356 numbers of independent variables. (A) 140 independent variables, (B) 14 independent variables
357 (reduced dimensions).

358 Table 1 Identification of the Significantly Different Endogenous Metabolites in the Model Rats'
359 Urine.

361 4. Discussion

362 PMS is a typical stress-related emotional disease that affects 8 % of women of child-bearing age.
363 Emotional symptoms, such as anxiety, must be consistently present to diagnose PMS. The electrical
364 stimulation on female SD rats can produce a series of abnormal behavioural and physiological
365 responses that are similar to the emotional symptoms of PMS, including a reduction in exploratory
366 behaviour and plasma hormone level alterations (prolactin, estradiol and progesterone)²⁰. Previously, a
367 serum metabolomics approach based on UPLC/QTOF-MS had been developed to evaluate the

368 therapeutic effects of the *Baixiangdan* capsule on liver-Qi invasion syndrome PMS rats ²². The
369 therapeutic mechanism of the *Baixiangdan* capsule is related to the regulation of the metabolism of
370 corticosteroids, oestrogen and excitatory/inhibitory amino acid neurotransmitters.

371 The present study developed a urinary metabolomics method on the basis of UPLC-QTOF/MS to
372 investigate the temporal variations in the metabolic profiles of rats that underwent electric stimulation
373 in 5 days. AI techniques integrating neurofuzzy logic and neural networks were applied for the first
374 time here to find and understand the correlation of the selected potential biomarkers to the occurrence
375 and development of liver-Qi syndrome PMS induced by electric stimulation. The minimal dataset,
376 containing 14 differential features (metabolites) that are sufficient to explain the variability of the
377 endogenous metabolites associated with the dynamic pathological processes induced by electric
378 stimulation, was obtained using neurofuzzy logic modelling. Therefore, the 14 differential feature
379 metabolites were considered to be potential biomarkers for discriminating the different urine metabolic
380 profiles in different days. Seven sub-models, implying hidden interactions between 14 potential
381 biomarkers, were constructed according to the intelligible rules in an “if then” format explicitly
382 representing the cause-effect relationships contained in the experimental data during the neurofuzzy
383 logic modelling. However, these important correlations among variables are usually neglected in the
384 commonly used multivariate analysis with VIP values as the weight sum of the PLS loadings to
385 evaluate the variable contributions for distinguishing different metabolic states.

386 As shown in Table 1, nine of the fourteen differential endogenous metabolites discovered using the
387 neurofuzzy logic model were found to be monoamine neurotransmitter metabolites, including
388 2-aminoadipic acid (**1**), hippuric acid (**10**), 4-hydroxyglutamate (**5**), 2,3-diaminopropionic acid (**12**),
389 spermine (**15**), L-phenylalanine (**16**), proline (**17**), pantothenol (**18**) and L-methionine (**19**). These
390 results are consistent with previous reports regarding the pathogenesis of PMS, which is related to

391 amino acid metabolism and neural signal transmission.
392 Glutamate is the most abundant fast excitatory neurotransmitter in the mammalian nervous system,
393 which is responsible for mediating a broad range of nervous system functions *via* glutamate receptors.
394 It may be involved in the metabolism of proteins and glucose in brain, as well as promoting oxidation
395 and improving the function of the central nervous system²⁴. The previously study have explored the
396 relationship between pathogenesis of PMS and glutamate by determining the concentrations of
397 glutamate in serum and different regions of brain (including hypothalamus, limbic lobe, frontal cortex
398 and hippocampus) using pre-column derivatization HPLC method. The glutamate levels in serum,
399 hypothalamus and limbic lobe decreased significantly in PMS model rats when compared with normal
400 ones, while those in frontal cortex and hippocampus were found to be increasing after model
401 establishment²⁵.

402 2-aminoadipic acid (**1**) is a primary metabolite in the lysine metabolic pathway, which antagonizes
403 neuro-excitatory activity modulated by the glutamate receptor, N-methyl-D-aspartate (NMDA).
404 Aminoadipic has also been shown to inhibit the production of kynurenic acid, a broad spectrum
405 excitatory amino acid receptor antagonist²⁶. The disorder of 2-aminoadipic acid has been associated
406 with varying neurological symptoms²⁷. Meanwhile, the metabolism of lysine also rely on the regulation
407 of glutamate receptor, implied that the level of 2-aminoadipic acid in urine should be related to that of
408 glutamate.

409 4-hydroxyglutamate (**5**), an intermediate in the metabolism of gamma-hydroxyglutamic acid.
410 Specifically 4-hydroxyglutamate combines with 2-oxoglutarate to produce 4-hydroxy-2-oxoglutarate
411 and glutamate²⁸. Therefore, the level of 4-hydroxyglutamate should also be closely related to that of
412 glutamate. Hippuric acid (**10**) is an acyl glycine formed by the conjugation of benzoic acid with glycine
413 on the basis of the action of glycine N-acyltransferase. And glycine combines with α -ketoglutaric acid

414 could produce glyoxylic acid and glutamic acid. The up-regulation of these metabolites, including
415 2-aminoadipic acid (**1**), 4-hydroxyglutamate (**5**) and hippuric acid (**10**), in the urine represent an
416 increase in the excitatory amino acid glutamate²⁹.

417 In addition, shikimate-5-phosphate (**4**), which is the precursor of chorismic acid and tryptophan, was
418 also discovered by the two data mining approaches. Shikimate-5-phosphate has been reported to
419 participate in the metabolism of phenylalanine. Both L-phenylalanine (**16**) and tryptophan are required
420 for the biosynthesis of monoamine neurotransmitters and play an important role in the pathogenesis of
421 emotional disorders. Decreased phenylalanine levels were detected in the urine of the electric-stressed
422 rats, which was in agreement with other reports¹³. However, L-phenylalanine was only discovered via
423 the AI analysis, in addition to spermine (**15**), proline (**17**), pantothenol (**18**), L-methionine (**19**) and
424 xanthosine (**20**). Proline is also a derivative of glutamate, which generates hydroxyproline and then
425 decomposes into 4-hydroxyglutamate, an excitatory amino acid neurotransmitter.

426 Melatonin (**13**), which is involved in the metabolic pathway of 5-HT, was also found using the
427 neurofuzzy logic model. It has been suggested that PMS is related to a systemic imbalance of the
428 neurotransmitter 5-hydroxy tryptamine (5-HT)³⁰⁻³². The emergence of symptoms such as emotional
429 instability, irritability, and anxiety are related to a decrease in 5-HT levels³³. The increased melatonin
430 in the urine of the stressed rat model indicates the down-regulation of 5-HT. Melatonin exhibits
431 extensive physiological activities, and its daily and seasonal rhythms are considered to be closely
432 related to the functional regulation of immunity and the neuroendocrine and reproductive systems. The
433 biosynthesis of melatonin is also rhythmic, in addition to melatonin precursors and its related synthesis
434 enzymes, e.g., *N*-acetyltransferase, HIOMT, 5-HT³⁴. The rhythm of *N*-acetyltransferase and HIOMT
435 exhibit the same tendencies as melatonin, while 5-HT is the opposite³⁵. Therefore, a rise in melatonin
436 may be attributed to the premenstrual moods of dysphoria and irritability. Other biomarkers, such as

437 11-epi-prostaglandin F₂α (3) and 6-keto-prostaglandin F₁α (9) have been found to be involved in signal
438 transduction and the regulation of physiological activities, such as the synthesis of lipoproteins and
439 carbohydrates, which are related to the development of stress/emotion-related diseases.


440 Genistein (7) was also identified as a differential component, and it has been reported to be related to
441 energy metabolism. Genistein is also a primary component of rat feed, which is made from soybeans.
442 The stress experiment may inevitably cause the loss of appetite; therefore, the reduction of genistein in
443 the urine between the experimental and initial states could be due to various factors.

444 The predictive abilities of these 14 potential biomarkers were then evaluated using a neural network
445 model. When using neural network algorithms, intelligible rules are generated on the basis of “unseen”
446 data to provide accurate predictions. This is different from the cross validation approach that is
447 commonly applied in multivariate analyses and neurofuzzy logic, where the test data are used. Therefore,
448 the evaluated results obtained using neural network modelling are more credible. The 14 potential
449 biomarkers discovered using the AI analysis closely related to the occurrence and development of
450 liver-Qi syndrome PMS, indicating that the AI appeared to be more effective than the PLS-DA analysis
451 for the data mining.

452 Upon analysing the dynamic trajectories of the holistic metabolic profiles for the 5 different days of
453 electric stimulation in the PLS-DA score plots, the greatest difference was observed on day 2, which
454 indicates that as a response to the electric stimulation, the metabolism of the endogenous substances
455 and the metabolic profiles in the urine were significantly altered compared to the initial state. From day
456 3 to day 5, the trajectory direction gradually moved back to that of day 1, meaning that the
457 experimental animals accommodated for the electric stimulation, and the stress states were relieved; the
458 same intensity of stimulation could not cause a similar response. Therefore, with the exception of the
459 fact that urine metabolites are the final products of all physiological and pathological processes, the

460 adaption to the stress state and the potential biomarkers discovered in this study showed significant
461 differences to the ones that were discovered in previous serum metabolomics studies.

462 The *Baixiangdan* capsule is a new TCM prescription that has been used for the treatment of PMS³³⁻³⁴.
463 Different urine metabolite patterns were observed *via* PLS-DA, implicating the potential efficacy of the
464 *Baixiangdan* capsule on the electric-stress rat model. As shown in Figure 4, the average intensities of
465 2-aminoadipic acid, 4-hydroxyglutamate and melatonin in the urine of the different groups (CG, SG
466 and BCDG) were compared. During the first four days, compared with the levels observed in the CG
467 rats, the levels of the three metabolites in the SG rats gradually rose. However, in the treatment group
468 (BCDG), the levels decreased significantly compared to the SG rats. The results suggest that several

469 
470 Figure 4 A comparison of the major differential metabolites in the urine of the stress group (SG), the
471 control group (CG) and the *Baixiangdan* capsule-dosed group (BCDG). (A) 2-aminoadipic acid, (B)
472 4-hydroxyglutamate, (C) melatonin. #*p* < 0.05 *vs.* the CG rats, **p* < 0.05 *vs.* the SG rats (student's
473 patients suffering from PMS; therefore, relieving the typical psychological symptoms, such as
474 emotional instability, irritability and anxiety.

474

475

476

477

478 In the present study, AI analysis was applied for the discovery of potential biomarkers related to the
479 dynamic pathological processes of liver-Qi invasion syndrome PMS in an induced-stress rat model for
480 the first time. The explored potential biomarkers have been proved to be valuable according the
481 biochemical interpretations referred to the corresponding literatures. However, some remaining
482 questions would still be necessary and essential to regard the roles of obtained biomarkers in certain

483 metabolic pathways, and better understand the exact pathogenesis of PMS. For example, validation of
484 these discovered biomarkers on the basis of biological experimental evidences; illustration on
485 corrections of obtained potential biomarkers in serum/plasma and urine; precise quantitative
486 determinations of potential biomarkers to give rational thresholds for disease diagnosis and efficacy
487 evaluation, *etc.* should be solved in the following investigations. These problems would be solved in
488 the sequential investigations.

489 **5. Conclusions**

490 A urinary metabolomics method based on ultra-performance liquid chromatography coupled with
491 quadrupole/time-of-flight mass spectrometry (UPLC-QTOF/MS) was employed to investigate the
492 pathogenesis and therapeutic effect of the *Baixiangdan* capsule on electric-induced stress in rats for five
493 days. Artificial intelligence technology (artificial neural networks and neurofuzzy logic) was used for
494 the first time for the discovery of the differential metabolites in the data mining of this metabolomics
495 study. The ANN model exhibited a desirable fitness and predictive ability, and the metabolic signatures
496 discovered using neurofuzzy logic were helpful for understanding the hidden cause-effect relationships
497 between the experimental data. The potential mechanism of the electric stress was elucidated, and
498 excitatory amino acid neurotransmitters related to the typical psychological symptoms of PMS,
499 including anxiety and irritability, were found to be potential biomarkers for the diagnosis and
500 therapeutic evaluation of PMS. This research demonstrates that artificial intelligence technologies are
501 powerful and promising tools for modelling complex metabonomic data and discovering hidden
502 knowledge regarding potential biomarkers associated with the development of diseases, which is also
503 suitable for other complex biological data sets.

504 **Ethical conduct of research**

505 The authors state that they have obtained appropriate institutional review board approval or have

506 followed the principles outlined in the Declaration of Helsinki for all human or animal experimental
507 investigations.

508

509 **Acknowledgments**

510 This work was sponsored by the International Cooperation Projects of the Ministry of Science and
511 Technology (MOST) in China (No. 2010DFA32420) and the National Natural Science Foundation of
512 China (No. 81130066).

513 **Supporting Information Available**

514 **Figure S1** The PCA score plot of the rat urine data on days 0 (prior to the electrically induced stress), 1,
515 2, 3, 4 and 5. The toleration ellipse curve in the PCA score plot was drawn using Hotelling's T2 with a
516 confidence value of 95 %.

517 **Figure S2** PLS-DA scores plots of normal rat urine data on days 0, 1, 2, 3, 4 and 5. Figure S2 The
518 PLS-DA score plots of the rat urine data on days 0 (prior to the electrically induced stress), 1, 2, 3, 4 and
519 5. (A) The dynamic mean-centred PLS-DA score plot of the rat urine data from the model group and the
520 control group ($Q^2Y_{(cum)}=0.912$, $R^2X_{(cum)}=0.427$, $R^2Y_{(cum)}=0.952$). (B) The dynamic mean-centred
521 PLS-DA score plot of the rat urine data from the *Baixiangdan*-dosed group and the control group
522 ($Q^2Y_{(cum)}=0.877$, $R^2X_{(cum)}=0.423$, $R^2Y_{(cum)}=0.973$).

523 **Figure S3** PLS-DA scores plots of normal rat urine data on days 0, 1, 2, 3, 4 and 5.

524 **References**

- 525 1. E. J. Want, I. D. Wilson, H. Gika, G. Theodoridis, R. S. Plumb, J. Shockcor, E. Holmes, and J. K.
526 Nicholson, *Nat. Protoc.*, 2010, **5**, 1005–1018.
- 527 2. J. K. Nicholson, *Mol. Syst. Biol.*, 2006, **2**, 52.
- 528 3. J. C. Lindon, J. K. Nicholson, E. Holmes, H. Antti, M. E. Bollard, H. Keun, O. Beckonert, T. M.
529 Ebbels, M. D. Reily and D. Robertson, *Toxicol. Appl. Pharm.*, 2003, **187**, 137–146.
- 530 4. X. P. Liang, X. Chen, Q. L. Liang, H. Y. Zhang, P. Hu, Y. M. Wang, and G. A. Luo, *J. Proteome. Res.*,
531 2011, **5**, 790–799.
- 532 5. P. Wang, H. Sun, H. Lv, W. Sun, Y. Yuan, Y. Han, D. Wang, A. Zhang and X. J. Wang, *J. Pharm.*
533 *Biomed. Anal.*, 2010, **53**, 631–645.
- 534 6. B. Sun, L. Li, S. M. Wu, Q. Zhang, H. J. Li, H. B. Chen, F. M. Li, F. T. Dong and X. Z. Yan, *Anal.*
535 *Biochem.*, 2009, **395**, 125–133.
- 536 7. H. M. Jia, Y. F. Feng, Y. T. Liu, X. Chang, L. Chen, H. W. Zhang, G. Ding and Z. M. Zou, *PLoS One*,
537 2013, **8**, e63624.
- 538 8. L. D. Han, J. F. Xia, Q. L. Liang, Y. Wang, Y. M. Wang, P. Hu, P. Li, and G. A. Luo, (2011), *Anal.*
539 *Chim. Acta*, 2011, **689**, 85–91.
- 540 9. Z. T. Jiang, J. B. Sun, Q. L. Liang, Y. F. Cai, S. S. Li, Y. Huang, Y. M. Wang and G. A. Luo, *Talanta*,
541 2011, **84**, 298–304.
- 542 10. X. Li, X. Lu, J. Tian and G. W. Xu, *Anal. Chem.*, 2009, **81**, 4468–4475.
- 543 11. J. Chen, Y. Zhang, X. Y. Zhang, R. Cao., S. L. Chen, Q. Huang, X. Lu, X. P. Wang, X. H. Wu, C. J.
544 Xu, G. W. Xu and X. H. Lin, *Metabolomics.*, 2011, **7**, 614–622.
- 545 12. J. S. R. Jang, C. T. Sun and E. Mizutani, *Neuro-fuzzy and soft computing: a computational approach*
546 *to learning and machine intelligence*. Prentice-Hall International (UK) Limited, London, 1997.

- 547 13. Q. Shao, R. C. Rowe and P. York, *Eur. J. Pharm. Sci.*, 2006, **28**, 394–404.
- 548 14. Q. Shao, R. C. Rowe and P. York, *Eur. J. Pharm. Sci.*, 2007, **31**, 129–136.
- 549 15. P. I. Sundstrom, S. Smith and M. Gulinello, *Arch. Womens Ment Health*, 2003, **6**, 23–41.
- 550 16. M. Steiner, *Lancet.*, 2000, **356**, 1126–1127.
- 551 17. H. Gao, (2009), Research progress on the correlation between anger pathogenesis and Premenstrual
552 syndrome. *Chin. J. Med. Guide*, 2009, **11**, 283–285.
- 553 18. Y. Zhao, H. Xu, L. M. Lei and H. L. Zhu, *Int. J. Lab. Med.*, 2013, **34**, 2627–2628.
- 554 19. S. G. Sun, Y. Lu, A. H. Wang, X. L. Sui, M. Huang, J. Liu, J. Zhu, Z. F. Li, H. Y. Zhang and M. Q.
555 Qiao, *China Pharmacy*. 2011, **22**, 209–211.
- 556 20. H. Y. Zhang, M. Q. Qiao, W. C. Zhu and J. Wang, *Chin. Trad. Pat. Med.*, 2002, **24**, 118–119.
- 557 21. L. Li, P. Sun, Q. L. Liang, H. Y. Zhang, Y. Wang, M. Q. Qiao and G. A. Luo, *Chin. Trad. Pat. Med.*,
558 2011, **33**, 762–767.
- 559 22. Y. M. Li, B. Zhang and X. H. Fan, *Chin. Trad. Pat. Med.*, 2009, **31**, 1690–1694.
- 560 23. G. A. Luo, Y. M. Wang, Q. L. Liang and Q. F. Liu, *Systems Biology for Traditional Chinese*
561 *Medicine*, Science Press, Beijing, China, 2010.
- 562 24. X. Zhou and X. Q. Wang, (2003), *Chin. J. Neurosci.*, 2003, **19**, 130–133 .
- 563 25. L. Sun, Analysis of progesterone and amino acid in serum and different brain regions of rats with
564 premenstrual syndrome liver -qi invasion . Master thesis, Shandong University of Traditional
565 Chinese Medicine, 2008.
- 566 26. H.Q. Wu, U. Ungerstedt, R. Schwarcz, *Eur J Pharmacol*. 1995, **25**, 55–61
- 567 27. K. Danhauser , S.W. Sauer, T.B. Haack, T. Wieland, C. Staufner, E. Graf, J. Zschocke, T.M. Strom,
568 T. Traub, J.G. Okun, T. Meitinger, G.F. Hoffmann, H. Prokisch, S. Kölker. *Am J Hum Genet*. 2012,
569 **91**, 1082–1087.

- 570 28. A. Goldstone , E. Adams, *J Biol Chem.* 1962, **237**, 3476–3485.
- 571 29. X. Y. Wang, C. Y. Zeng, J. C. Lin, T. L. Chen, T. Zhao, Z. Y. Jia, X. Xie, Y. P. Qiu, M. M. Su, T.
572 Jiang, M. W. Zhou, A. H. Zhao and W. Jia, *J. Proteome. Res.*, 2012, **11**, 6223–6230.
- 573 30. X. Wang, T. Zhao, Y. P. Qiu, T. Jiang, M. W. Zhou, A. H. Zhao and W. Jia, *J. Proteome. Res.*, 2009, **8**,
574 2511–2518.
- 575 31. S. Ramcharan, E. J. Love, G. H. Fick and A. Goldfien, *J. Clin. Epidemiol.*, 1992, **45**, 377– 392 .
- 576 32. J. E. Borenstein, B. B. Dean, J. Endicott, J. Wong, C. Brown, V. Dickerson and K. A. Yonkers, *J.*
577 *Reprod. Med.*, 2003, **48**, 515– 524.
- 578 33. A. Rapkin, *Psychoneuroendocrinol.*, 2003, **28**, 39 – 53.
- 579 34. J. Axelrod and H. Weissbach, *Science*, 1960, **131**, 1312 – 1313.
- 580 35. M. Abe and T. Masanori, *Exp. Eye Res.*, 1999, **68**, 255-262.
- 581 36. X. H. Liu, H. Y. Zhang and Q. T. Zhao, *J. Trad. Chin. Med.* 2007, **48**, 834–836.
- 582 37. Y.G. Hu and L.Xue, *Pharmacol. Clin. Chin. Mater. med.* 2007, **23**, 151–153.

583 **Table 1 Identification of the Significantly Different Endogenous Metabolites in the Model Rats' Urine**

No.	t _R (min)	m/z	Elemental composition	identification results	Data mining	Model ^b
1	5.75	162.0759	C ₁₆ H ₁₂ NO ₄	2-aminoadipic acid ^c	PLS-DA, ANN	+(↑) ^a
2	6.42	130.0869	C ₅ H ₈ NO ₃	5-oxoproline	PLS-DA	+(↑)
3	19.19	353.2466	C ₂₀ H ₃₃ O ₅	11-epi-prostaglandin F2α	PLS-DA, ANN	+(↓)
4	10.54	255.0259	C ₇ H ₁₂ O ₈ P	shikimate-5-phosphate	PLS-DA, ANN	+(↑)
5	5.30	164.0805	C ₅ H ₁₀ NO ₅	4-hydroxyglutamate ^c	PLS-DA, ANN	+(↑)
6	19.33	373.2744	C ₁₆ H ₂₉ N ₄ O ₄ S	biocytin	PLS-DA	+(↓)
7	12.47	271.0607	C ₁₅ H ₁₁ O ₅	genistein ^c	PLS-DA, ANN	+(↓)
8	8.27	252.1595	C ₁₀ H ₁₄ N ₅ O ₃	deoxyadenosine	PLS-DA	+(↓)
9	19.19	371.2589	C ₂₀ H ₃₅ O ₆	6-keto-prostaglandin F1α	PLS-DA	+(↓)
10	4.60	180.0619	C ₉ H ₁₀ NO ₃	hippuric acid ^c	PLS-DA, ANN	+(↑)
11	5.78	144.0601	C ₆ H ₁₀ NOS	5-(2-hydroxyethyl)-4-methylazole	PLS-DA	+(↑)
12	4.69	105.0683	C ₃ H ₈ N ₂ O ₂	2,3-diaminopropionic acid	PLS-DA, ANN	+(↓)
13	6.30	233.1219	C ₁₃ H ₁₇ N ₂ O ₂	melatonin ^c	PLS-DA, ANN	+(↑)
14	4.60	118.0921	C ₅ H ₁₂ NO ₂	5-amino-valerate	PLS-DA	+(↓)
15	16.31	203.1827	C ₁₀ H ₂₇ N ₄	spermine ^c	ANN	+(↓)
16	1.03	166.0808	C ₉ H ₁₂ NO ₂	L-phenylalanine ^c	ANN	+(↓)
17	5.78	116.0722	C ₅ H ₁₀ NO ₄	proline ^c	ANN	+(↑)
18	8.26	206.1565	C ₉ H ₂₀ NO ₄	pantothenol	ANN	+(↓)
19	1.06	150.0911	C ₅ H ₁₂ NO ₂ S	L-methionine ^c	ANN	+(↑)
20	11.34	285.0753	C ₁₀ H ₁₂ N ₄ O ₆	xanthosine	ANN	+(↓)

584 ^a “↑” represents a higher level of metabolites, whereas “↓” represents a lower level of metabolites. All of the data represent the
585 intensity values of the metabolites on day 5. “+” represents a statistically significant difference ($p < 0.05$).^b Compared to the initial state.

586 ^c Confirmed using authentic standards.

Figure legends

Figure 1 The work flow of the data analyses using AI techniques, including reducing the variables using a neurofuzzy logic model and the predictive ability assessment using a neural network model.

Figure 2 The representative base peak intensity chromatograms of the rat urine obtained using the ESI positive mode of the UPLC-QTOF/MS. (A) normal group; (B) model group; (C) *Baixiangdan* capsule-dosed group.

Figure 3 The predictions given by the ANN models generated using a dataset containing various numbers of independent variables. (A) 140 independent variables, (B) 14 independent variables.

Figure 4 A comparison of the major differential metabolites in the urine of the model group (MG), the normal group (NG) and the *Baixiangdan* capsule-dosed group (BADG). (A) 2-aminoadipic acid, (B) 4-hydroxyglutamate, (C) melatonin. [#] $p < 0.05$ vs. the NG rats, * $p < 0.05$ vs. the MG rats (student's t-test).




Figure 1 The work flow of the data analyses using AI techniques, including reducing the variables using a neurofuzzy logic model and the predictive ability assessment using a neural network model.




Figure 2. The representative base peak intensity chromatograms of the rat urine obtained using the ESI positive mode of the UPLC-QTOF/MS. (A) control group (CG); (B) stress group; (C) *Baixiangdan* capsule dosed group (BCDG).




Figure 3 The predictions given by the ANN models generated using a dataset containing various numbers of independent variables. (A) 140 independent variables, (B) 14 independent variables (reduced dimensions).




Figure 4 A comparison of the major differential metabolites in the urine of the stress group (SG), the control group (CG) and the *Baixiangdan* capsule-dosed group (BCDG). (A) 2-aminoadipic acid, (B) 4-hydroxyglutamate, (C) melatonin. # $p < 0.05$ vs. the CG rats, * $p < 0.05$ vs. the SG rats (student's t-test).

Graphical Abstract

An integrating application of multivariable analysis and artificial intelligence technology (artificial neural networks and neurofuzzy logic) was firstly used to find out potential biomarkers related to the occurrence and development of liver-Qi syndrome PMS induced by electric stimulation in rats.

